Joleen M. Hubbard, MD

Articles by Joleen M. Hubbard, MD

Challenges With Molecular Testing in Metastatic Colorectal Cancer

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 16th 2023

A comprehensive discussion on the barriers to molecular testing in metastatic colorectal cancer, along with challenges in utilizing these tests in the real-world setting.

Circulating Tumor DNA to Guide Treatment Selection for mCRC

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 16th 2023

Panelists consider the potential role for circulating tumor DNA to inform the selection of therapy for patients with metastatic colorectal cancer.

Role of Tissue Versus Circulating Tumor DNA in Molecular Testing in mCRC

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 9th 2023

Shared insight on the value tissue and circulating tumor DNA respectively provide in molecular testing for patients with metastatic colorectal cancer.

Overview of Molecular Testing in Metastatic Colorectal Cancer (mCRC)

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Pashtoon M. Kasi, MBBS, MD, MS,Kanwal Raghav, MD,Joel R. Hecht, MD

February 9th 2023

Experts in metastatic colorectal cancer management highlight the role of molecular testing and testing modalities available in the academic and community settings.

Joleen M. Hubbard, MD, associate professor, oncology, consultant, practice chair, vice chair, Division of Medical Oncology, Department of Oncology, Mayo Clinic.

Dr. Hubbard on the Use of the PolyPEPI1018 Vaccine Plus Chemotherapy in Metastatic CRC

ByJoleen M. Hubbard, MD

January 27th 2023

Joleen M. Hubbard, MD, discusses key survival data from the phase 1b study of the PolyPEPI1018 vaccine and the impact of these findings on continued investigations of this vaccine in metastatic colorectal cancer.

Tucatinib plus trastuzumab in patients (pts) with HER2-Positive Metastatic Colorectal Cancer (mCRC): Patient Reported Outcomes from MOUNTAINEER

ByJoleen M. Hubbard, MD

October 5th 2022

Dr Hubbard reviews patient reported outcomes from the MOUNTAINEER trial, which evaluated the combination of tucatinib plus trastuzumab in patients with HER2-positive metastatic colorectal cancer.

Joleen M. Hubbard, MD

Articles by Joleen M. Hubbard, MD

Challenges With Molecular Testing in Metastatic Colorectal Cancer

Circulating Tumor DNA to Guide Treatment Selection for mCRC

Role of Tissue Versus Circulating Tumor DNA in Molecular Testing in mCRC

Overview of Molecular Testing in Metastatic Colorectal Cancer (mCRC)

Dr. Hubbard on the Use of the PolyPEPI1018 Vaccine Plus Chemotherapy in Metastatic CRC

Tucatinib plus trastuzumab in patients (pts) with HER2-Positive Metastatic Colorectal Cancer (mCRC): Patient Reported Outcomes from MOUNTAINEER

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma